Humanwell Healthcare's HW231019 enters phase II for acute pain

Humanwell Healthcare Group Co., Ltd. announced its holding subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd., has advanced the HW231019 tablet into Phase II clinical trials. The tablet received approval from the National Medical Products Administration in March 2025 for a clinical trial of its indicated use: acute pain treatment. The Phase II study aims to evaluate the efficacy and safety of HW231019 in post-abdominal surgery pain and to explore optimal dosing.

The company's cumulative research and development investment in the HW231019 project totals approximately RMB20,000,000. According to Insight database statistics, one company currently has a similar drug in Phase II/III, four in Phase II, and two in Phase I for acute pain indications in China.

The company reminded investors of the inherent risks in pharmaceutical R&D, given the lengthy and complex process from development to market approval, emphasizing that the product must complete all required clinical trials and receive approval from the National Medical Products Administration before market launch.